Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › VRDN

RICE HALL JAMES & ASSOCIATES, LLC position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

RICE HALL JAMES & ASSOCIATES, LLC reported holding 1,235,840 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$25.4M, representing 1.35% of its reported portfolio and ranking #21 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)1.24M sh
Reported value held$25.45M
Portfolio Weight1.35%
First reportedQ4 2024
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RICE HALL JAMES & ASSOCIATES, LLC's VRDN position evolved

RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in VRDN in Q4 2024 at 53,375 shares (US$1.0M). The position peaked in Q4 2025 at 884,532 shares, worth US$27.5M. Across 8 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 7 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,235,840 shares valued at US$25.4M — an increase of 59,934 shares quarter over quarter.. Notable position changes include a 580% increase in Q1 2025 (shares rose 4% over the following quarter), a 42% increase in Q2 2025 (shares rose 54% over the following quarter), a 65% increase in Q3 2025 (shares rose 44% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 53.38K $1.02M New
Q1 2025 362.89K $4.89M Add
Q2 2025 515.62K $7.21M Add
Q3 2025 851.66K $18.38M Add
Q4 2025 884.53K $27.53M Add
Q1 2026 898.61K $17.58M Add
Q2 2026 1.18M $21.60M Add
Q3 2026 1.24M $25.45M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has RICE HALL JAMES & ASSOCIATES, LLC held VRDN?

RICE HALL JAMES & ASSOCIATES, LLC has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is RICE HALL JAMES & ASSOCIATES, LLC's current position in VRDN?

As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 1.24M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $25.45M, representing 1.35% of its reported portfolio and ranking #21.

Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling VRDN?

In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC increased its position in VRDN. The position peaked in Q4 2025 at 884.53K shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.